Extracorporeal versus peritoneal ultrafiltration in diuretic-resistant congestive heart failure--a review

Zofia Wańkowicz, Agnieszka Próchnicka, Anna Olszowska, Daniel Baczyński, Paweł Krzesiński, Mirosław Dziuk, Zofia Wańkowicz, Agnieszka Próchnicka, Anna Olszowska, Daniel Baczyński, Paweł Krzesiński, Mirosław Dziuk

Abstract

Diuretic-resistant congestive heart failure in the form of type 2 cardiorenal syndrome is a problem of growing significance in everyday clinical practice because of high morbidity and mortality. There has been scant progress in the treatment of overhydration, the main cause of symptoms in this group of patients. The aim of our review is to present recent advances in the ultrafiltration therapy of congestive heart failure, with special attention to the new dedicated device for extracorporeal isolated ultrafiltration, as well as modifications of peritoneal dialysis in the form of peritoneal ultrafiltration with icodextrin solution and incremental peritoneal dialysis. Technical and clinical features, costs and potential risks of available devices for isolated ultrafiltration are presented. This method should be reserved for patients with true diuretic resistance as part of a more complex strategy aiming at the adequate control of fluid retention. Peritoneal ultrafiltration is presented as a viable alternative to extracorporeal ultrafiltration because of medical and psychosocial benefits of home-based therapy, lower costs and more effective daily ultrafiltration. In conclusion, large, properly randomized and controlled clinical trials with long-term follow-up will be essential in assessing the logistics and cost-effectiveness of both methods. Most importantly, however, they should be able to evaluate the impact of both methods on preservation of renal function and delaying the progression of heart failure by interrupting the vicious circle of cardiorenal syndrome. Our review is supplemented with the case report of the use of peritoneal ultrafiltration with a single 12-hour nighttime icodextrin exchange as a life-saving procedure in a patient with congestive heart failure resistant to pharmacological treatment.<br />

Figures

Figure 1
Figure 1
Impedance cardiography at the beginning of the ultrafiltration treatment (A) and 6 months after the initiation of peritoneal ultrafiltration protocol (B).

References

    1. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.
    1. Fonarow GC. ADHERE Scientific Advisory Committee, The Acute Decompensated Heart Failure National Registry (ADHERE): opportunites to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(Suppl 7):S21–30.
    1. American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas, TX: American Heart Association; 2005.
    1. United Nations Economic Commissions for Europe (UNECE) Trends in Europe and North America. The statistical yearbook of the Economic Commission for Europe (Web page) Geneva: UNECE; 2003. [assesed May 25, 2007]. [Available at: .
    1. Lloyd-Jones D, Adams R, Camethon M, et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480–86.
    1. Korewicki J, Browarek A, Zembala M, et al. Polish registry of patients with severe heart failure scheduled for heart transplant POLKARD-HF 2003–2007. Folia Cardiologica Excerpta. 2008;3:403–21.
    1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235.
    1. Jessup M, Brozena S. Heart Failure. N Engl J Med. 2003;348:2007–18.
    1. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877–89.
    1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 2008;29( 19):2388–442.
    1. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91(10):2504–7.
    1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes; current state and framework for future research. Circulation. 2005;112:3958–68.
    1. Wertman BM, Gura V, Swarz ER. Ultrafiltration for the Management of Acute Decompensated Heart Failure. J Card Fail. 2008;9(14):754–55.
    1. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631–39.
    1. Jessup M, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119(14):1977–2016.
    1. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.
    1. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg. 2005;129(1):9–17.
    1. Krishnan A, Oreopoulos DG. Peritoneal dialysis in congestive heart failure. Adv Perit Dial. 2007;23:82–89.
    1. Sánchez JE, Ortega T, Rodríguez C, et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant. 2010;25:605–10.
    1. Fiaccadori E, Regolisti G, Maggiore U, et al. Ultrafiltration in heart failure. Am Heart J. 2011;161:439–49.
    1. Asaba H, Bergstrom J, Furst P, et al. Treatment of diuretic-resistant fluid retention with ultrafiltration. Acta Med Scand. 1978;204:145–49.
    1. Jaski BE, Ha J, Denys BG, et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003;9:227–31.
    1. Liang KV, Hiniker AR, Williams AW, et al. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail. 2006;12:707–14.
    1. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–46.
    1. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation. 2008;117:975–83.
    1. Bouman CSC, Van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Blood Purif. 1998;16(5):261–68.
    1. Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cut-off hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004;43(3):444–453.

    1. Gambro Internal data- 2572-SepteX clearances

    1. Haase M, Bellomo R, Baldwin I, et al. Hemodialysis Membrane With a High-Molecular-Weight Cutoff and Cytokine levels In Sepsis Complicated by Acute Renal Failure: A Phase 1 Randomized Trial. Am J Kidney Dis. 2007;50(2):296–304.
    1. Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis. Heart Fail Rev. 2011
    1. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132–43.
    1. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.
    1. Costanzo MR, Saltzberg M, O’Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047–51.
    1. Costanzo MR, Guglin ME, Saltzberg MT, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.
    1. Jaski BE, Romeo A, Ortiz B, et al. Outcomes of volume-overloaded cardiovascular patients treated with ultrafiltration. J Card Fail. 2008;14:515–20.
    1. Rogers HL, Marshall J, Bock J, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. 2008;14:1–5.
    1. Costanzo MR, Agostoni P, Marenzi G. Extracorporeal fluid removal in heart failure patients. Contrib Nephrol. 2010;164:173–98.
    1. Kazory A, Ejaz AA, Ross EA. Ultrafiltration for heart failure: how fast should we move? Am Heart J. 2009;157:205–7.
    1. Thodis E, Passadakis P, Vargemezis, Oreopoulos PG. Peritoneal dialysis: better than, equal to, or worse than hemodialysis? Perit Dial Int. 2001;21:25–35.
    1. Wańkowicz Z. Peritoneal dialysis – the role in the integrated renal care, pitfalls and benefits of therapy. Advances in Clinical and Experimental Medicine. 2003;12:2. .
    1. Wańkowicz Z. Peritoneal dialysis and its role in the demography and epidemiology of chronic kidney disease. Pol Arch Int Med. 2009;119:810–13.
    1. Gotloib L, Fudin R, Yakubovich M, Vienken J. Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation. Nephrol Dial Transplant. 2005;20(Suppl 7):vii, 32–36.
    1. Ryckelynck JP, Lobbedez T, Valette B, et al. Peritoneal ultrafiltration and treatment -resistant heart failure. Nephrol Dial Transplant. 1998;13(Suppl 41):56–59.
    1. Díez Ojea B, Rodríguez Suárez C, Vidau P, et al. Peritoneal dialyisis role in heart failure treatment, experience in our center. Nefrologia. 2007;27:605–11.
    1. Montejo JD, Bajo MA, del Peso G, Selgas R. Role played by peritoneal dialysis in treating refractory heart failure. Nefrologia. 2010;30:21–27.
    1. Cnossen TT, Kooman JP, Konings CJ, et al. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif. 2010;30:146–52.
    1. Nakayama M, Nakano H, Nakayama M. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol. 2010;55:49–54.
    1. Takane H, Nakamoto H, Arima H, et al. Continuous ambulatory peritoneal dialysis is effective for patients with severe congestive heart failure. Adv Perit Dial. 2006;22:141–46.
    1. Wańkowicz Z. Peritoneal dialysis – 40 years of own experiences. Pol Arch Int Med. 2004;112(Spec):19–24.
    1. Próchnicka A, Olszowska A, Baczyński D, et al. Peritoneal dialysis as a therapeutic approach in congestive heart failure resistant to pharmacological treatment. Pol Arch Int Med. 2009;119:815–18.
    1. Próchnicka A, Olszowska A, Baczyński D, et al. Peritoneal dialysis as a therapeutic approach in congestive heart failure resistant to pharmacological treatment: case report. Pol Arch Int Med. 2009;119:834–37.
    1. Olszowska A, Zelichowski G, Waniewski J, et al. The kinetics of water transperitoneal transport during long-term peritoneal dialysis performed using icodextrin dialysis fluid. Pol Arch Int Med. 2009;119:305–10.
    1. Horl WH. Natriretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Investig Med. 2005;53:366–70.
    1. Zemel D, Imholz AL, de Waart DR, et al. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int. 1994;46:1422–30.
    1. Fincher ME, Campbell HT, Sklar AH, et al. Atrial natriuretic peptide (ANP) is removed by peritoneal dialysis in humans. Adv Perit Dial. 1989;5:16–19.
    1. Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508–15.
    1. Chung JH, Yun NR, Ahn CY, et al. Relationship between Serum N-Terminal Pro-Brain Natriuretic Peptide Level and Left Ventricular Dysfunction and Extracellular Water in Continuous Ambulatory Peritoneal Dialysis Patients. Electrolyte Blood Press. 2008;6(1):15–21.
    1. Mistry CD, Gokal R, Peers E, et al. A randomized multicenter clinical trial comparing isosmolar icodextrin with hypersmolar glucose solutions in CAPD. Kidney Int. 1994;46:496–503.
    1. Basile C, Chimienti D, Bruno A, et al. Efficacy of peritoneal dialysis with icodextrin in the long-term treatment of refractory congestive heart failure. Perit Dial Int. 2009;29:116–18.
    1. Paniaqua R, Orihuela O, Avila-Diaz M, et al. Echocardiographic, electrocardiographic and blood changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int. 2008;73:125–30.
    1. Mehrotra R, Nolph KD, Gotch F. Early initiation of chronic dialysis: role of incremental dialysis. Perit Dial Int. 1997;17:426–30.
    1. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105(14):1663–68.
    1. Packer M, Abraham WT, Mehra MR, et al. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol. 2006;47(11):2245–52.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir